Rituxan, a cancer medicine developed by Genentech and Biogen Idec, will continue to generate strong sales despite the introduction of Cephalon's Treanda because both drugs will probably be used as combination therapy to treat non-Hodgkin's lymphoma, according to a survey conducted by JPMorgan analyst Geoffrey Meacham. The survey, which involved 71 hematologists and cancer specialists, also showed that Treanda's launch will have minimal impact on Celgene Corp.'s Revlimid because the drugs cater to different cancer patients, Meacham said.

Full Story:

Related Summaries